Today, TAAR1 is being actively studied in the context of mental and neuropsychiatric diseases, and TAAR1 agonists are being considered therapeutic agents for schizophrenia, anxiety, and depression treatment [6,7,8,9]. Here, TAAR1 is linked to depressive symptom measurement.